	US 11,913,077 B2
	Compositions and methods for the diagnosis and treatment of ALT cancer
Charles Patrick Reynolds, Lubbock, TX (US); Balakrishna Koneru, Lubbock, TX (US); and Shawn Macha, Lubbock, TX (US)
Assigned to Texas Tech University System, Lubbock, TX (US)
Appl. No. 16/979,364
Filed by Texas Tech University System, Lubbock, TX (US)
PCT Filed Mar. 9, 2019, PCT No. PCT/US2019/021502 § 371(c)(1), (2) Date Sep. 9, 2020, PCT Pub. No. WO2019/173806, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/641,218, filed on Mar. 9, 2018.
Prior Publication US 2021/0002730 A1, Jan. 7, 2021
Int. Cl. C12Q 1/6886 (2018.01); A61K 31/198 (2006.01); A61K 31/439 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC C12Q 1/6886 (2013.01) [A61K 31/198 (2013.01); A61K 31/439 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12Q 2600/156 (2013.01)]

23 Claims

1. A method of treating a cancer in a patient, the method comprising:

obtaining a sample from the patient;

detecting a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, wherein the ALT phenotype is associated with an ATRX mutation; and

administering an effective amount of at least one of PRIMA-1 or APR-246 to the patient.